Ileal sodium/bile acid cotransporter

Description:

Description
  • Accession: Q12908
  • Swissprot: NTCP2_HUMAN
  • Organism: Homo sapiens
  • Gene: SLC10A2
  • Target class: Transporter

Drug Relations:

elobixibat
Elobixibat is an IBAT inhibitor approved in Japan for the treatment of chronic constipation. IBAT is the bile acid/sodium symporter responsible for the reuptake of bile acids in the ileum which is the initial step in the enterohepatic circulation. By inhibiting the uptake of bile acids, elobixibat increases the bile acid concentration in the gut, and this accelerates intestinal passage and softens the stool. Bioactivity details MOA